These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 30735815)

  • 1. Surgical Resection of SCLC: Prognostic Factors and the Tumor Microenvironment.
    Zhao X; Kallakury B; Chahine JJ; Hartmann D; Zhang Y; Chen Y; Zhang H; Zhang B; Wang C; Giaccone G
    J Thorac Oncol; 2019 May; 14(5):914-923. PubMed ID: 30735815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor infiltrating lymphocytes and PD-L1 expression in brain metastases of small cell lung cancer (SCLC).
    Berghoff AS; Ricken G; Wilhelm D; Rajky O; Widhalm G; Dieckmann K; Birner P; Bartsch R; Preusser M
    J Neurooncol; 2016 Oct; 130(1):19-29. PubMed ID: 27436101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human leukocyte antigen class II-based immune risk model for recurrence evaluation in stage I-III small cell lung cancer.
    Chen P; Zhao L; Wang H; Zhang L; Zhang W; Zhu J; Yu J; Zhao S; Li W; Sun C; Wu C; He Y; Zhou C
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34362829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distribution characteristics and prognosis of tumor-infiltrating lymphocytes in the brain metastases of small cell lung cancer: a retrospective cohort study.
    Qian H; Pang J; Wan C; Mei X; Liao J; Wang B; Milano MT; Suwinski R; Inno A; Du Y
    Transl Cancer Res; 2024 May; 13(5):2509-2517. PubMed ID: 38881925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High PD-L1 expression is associated with stage IV disease and poorer overall survival in 186 cases of small cell lung cancers.
    Chang YL; Yang CY; Huang YL; Wu CT; Yang PC
    Oncotarget; 2017 Mar; 8(11):18021-18030. PubMed ID: 28152514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Galectin-9-based immune risk score model helps to predict relapse in stage I-III small cell lung cancer.
    Chen P; Zhang L; Zhang W; Sun C; Wu C; He Y; Zhou C
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33082168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of immune microenvironment in small-cell lung cancer: Distribution of PD-L1 expression and prognostic role of FOXP3-positive tumour infiltrating lymphocytes.
    Bonanno L; Pavan A; Dieci MV; Di Liso E; Schiavon M; Comacchio G; Attili I; Pasello G; Calabrese F; Rea F; Favaretto A; Rugge M; Guarneri V; Fassan M; Conte PF
    Eur J Cancer; 2018 Sep; 101():191-200. PubMed ID: 30077124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FOXP3-based immune risk model for recurrence prediction in small-cell lung cancer at stages I-III.
    Jiang M; Wu C; Zhang L; Sun C; Wang H; Xu Y; Sun H; Zhu J; Zhao W; Fang Q; Yu J; Chen P; Wu S; Zheng Z; He Y; Zhou C
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34006632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung Cancer (SCLC).
    Carvajal-Hausdorf D; Altan M; Velcheti V; Gettinger SN; Herbst RS; Rimm DL; Schalper KA
    J Immunother Cancer; 2019 Mar; 7(1):65. PubMed ID: 30850021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD3, CD8, IFN-Ī³, tumor and stroma inflammatory cells as prognostic indicators for surgically resected SCLC: evidences from a 10-year retrospective study and immunohistochemical analysis.
    Fu M; Feng C; Wang J; Guo C; Wang Y; Gao R; Wang J; Zhu Q; Zhang X; Qi J; Zhang Y; Bian Y; Wang Z; Fang Y; Cao L; Hong B; Wang H
    Clin Exp Med; 2024 May; 24(1):99. PubMed ID: 38748269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Significance of programmed cell death-ligand 1 expression and its association with survival in patients with small cell lung cancer.
    Ishii H; Azuma K; Kawahara A; Yamada K; Imamura Y; Tokito T; Kinoshita T; Kage M; Hoshino T
    J Thorac Oncol; 2015 Mar; 10(3):426-30. PubMed ID: 25384063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved Prognosis and Increased Tumor-Infiltrating Lymphocytes in Patients Who Have SCLC With Neurologic Paraneoplastic Syndromes.
    Iams WT; Shiuan E; Meador CB; Roth M; Bordeaux J; Vaupel C; Boyd KL; Summitt IB; Wang LL; Schneider JT; Warner JL; Zhao Z; Lovly CM
    J Thorac Oncol; 2019 Nov; 14(11):1970-1981. PubMed ID: 31201935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the ResponseĀ of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
    Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
    J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of PD-L1 expression and CD8+ T cell infiltration in pulmonary neuroendocrine tumors.
    Wang H; Li Z; Dong B; Sun W; Yang X; Liu R; Zhou L; Huang X; Jia L; Lin D
    Diagn Pathol; 2018 May; 13(1):30. PubMed ID: 29789013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of PD-1 and PD-L1 on Tumor-Infiltrating Lymphocytes Predicts Prognosis in Patients with Small-Cell Lung Cancer.
    Sun C; Zhang L; Zhang W; Liu Y; Chen B; Zhao S; Li W; Wang L; Ye L; Jia K; Wang H; Wu C; He Y; Zhou C
    Onco Targets Ther; 2020; 13():6475-6483. PubMed ID: 32753888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: Comparison with tumor-infiltrating T cells and the status of oncogenic drivers.
    Kim MY; Koh J; Kim S; Go H; Jeon YK; Chung DH
    Lung Cancer; 2015 Apr; 88(1):24-33. PubMed ID: 25662388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low PD-1 Expression in Cytotoxic CD8
    Mazzaschi G; Madeddu D; Falco A; Bocchialini G; Goldoni M; Sogni F; Armani G; Lagrasta CA; Lorusso B; Mangiaracina C; Vilella R; Frati C; Alfieri R; Ampollini L; Veneziani M; Silini EM; Ardizzoni A; Urbanek K; Aversa F; Quaini F; Tiseo M
    Clin Cancer Res; 2018 Jan; 24(2):407-419. PubMed ID: 29074606
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinicopathological features and prognostic analysis of 247 small cell lung cancer with limited-stage after surgery.
    Liu L; Wei J; Teng F; Zhu Y; Xing P; Zhang J; Guo Y; Dong J; Ying J; Li J; Yang L
    Hum Pathol; 2021 Feb; 108():84-92. PubMed ID: 33245986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage I pulmonary squamous cell carcinoma.
    Yang CY; Lin MW; Chang YL; Wu CT; Yang PC
    Eur J Cancer; 2016 Apr; 57():91-103. PubMed ID: 26901614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of pulmonary resection in the diagnosis and treatment of limited-stage small cell lung cancer: revision of clinical diagnosis based on findings of resected specimen and its influence on survival.
    Iwata T; Nishiyama N; Nagano K; Izumi N; Mizuguchi S; Tsukioka T; Morita R; Chung K; Hanada S; Inoue K
    Gen Thorac Cardiovasc Surg; 2012 Jan; 60(1):43-52. PubMed ID: 22237738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.